Sort by
Refine Your Search
-
Listed
-
Category
-
Country
-
Program
-
Field
-
enhanced fluorescence (PEF), - identifying optimal properties of functionalized plasmonic nanoparticles to enhance the PEF effect, - characterizing and measuring the PEF enhancement of the developed fiber
-
for Vascular Translational Science (https://lvts.fr/ ). Objective: We are seeking to recruit a chemist with expertise in nanoparticle synthesis, functionalisation and characterisation to join the replication
-
gold–lipid nanoparticles for localized glioblastoma treatment, optimized through a Quality by Design approach supported by computational modeling. Following process and formulation optimization
-
hydrogel scaffold loaded with MIL-100 (an iron-based metal organic framework or Fe-MOF) and SBA-15 silica (an ordered mesoporous silica nanoparticle or MSN) to treat Hepatocellular Carcinoma. This scaffold
-
selection process for an indefinite employment contract within the framework of a Line of Research R&D line: Development of lipid nanoparticles in the context of immunotherapy and gene therapy https
-
nanoparticles. The project is a collaboration between researchers in the Schools of Chemistry and Computer Science, combining cutting edge machine learning methods with world-leading electron microscopy
-
Dalhousie University | Halifax Mid Harbour Nova Scotia Provincial Government, Nova Scotia | Canada | about 12 hours ago
and optimize advanced combination strategies, including hyperthermia-based interventions Lead nanoparticle characterization and complex bioconjugation/chemistry workflows Oversee immune profiling
-
nanoparticles such as Pt and Ir02 under oxygen and hydrogen evolution reaction conditions. About your role: Preparation of Pt and Ir02 nanoparticle model systems Electrocatalytic investigation of Pt and Ir02
-
products of an electrochemical reaction - Preparation of three types of ultrathin gold films on silicon: films formed from dense monolayers of gold nanoparticles, continuous gold films, and micrometric gold
-
matrices, fabricate nanoparticles for controlled immunomodulator delivery, and conduct in‑vitro biological assessment. Applicants must be able to start on 1 September 2026 and must hold – or be demonstrably